Different from Bujanow, most of the studies conducted administered oxytocin intranasally to patients with schizophrenia, except for Marotta et al., in which oxytocin was sublingually augmented to clozapine-treated patients with schizophrenia [118]. Here, OXT is linked to schizophrenia.